Abstract The Joint National Committee and the World Health Organization are in agreement
that hypertension in most patients who are treated is controlled inadequately and that rates …

Fifty years ago, investigators identified renin inhibition as the preferred pharmacologic
approach to blockade of the renin–angiotensin system. Renin is a monospecific enzyme that …

The renin system plays a key role in the pathology of hypertension and is influenced, both
directly and indirectly, by most antihypertensive agents. The system is the target of several …

Background—Pharmacological interruption of the renin-angiotensin system focuses on
optimization of blockade. As a measure of intrarenal renin activity, we have examined renal …

BACKGROUND: Despite the availability of many effective, well-tolerated drugs, a significant
proportion of treated hypertensive patients still have uncontrolled high blood pressure (BP) …

Aliskiren represents the first member in a new class of antihypertensive drugs. Inhibiting the
renin–angiotensin system at its rate-limiting step is an idea that has been pursued for> 30 …

The first oral direct renin inhibitor, aliskiren, recently received approval for the treatment of
hypertension. This article addresses the premise, promise, and potential limitations of this …

With the development of aliskiren, blockade of the renin–angiotensin–aldosterone system
(RAAS) at the level of the interaction of renin with a substrate has become a clinical reality …

Aliskiren is the first direct renin inhibitor for the treatment of hypertension. Clinical
experience from studies in over 14,000 patients has shown that aliskiren, alone or in …

Aliskiren is the first member of the new class of orally active direct renin inhibitors to receive
approval from the United States Food and Drug Administration for the treatment of …